News
Hosted on MSN1mon
Senate panel questions Novo Nordisk CEO over decision to discontinue this popular insulinAll patients with Type 1 diabetes and some with Type 2 diabetes rely on insulin to survive. Sen, Maggie Hassan, D- New Hampshire, said Levemir is a critical insulin and questioned the company's ...
A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...
(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by ...
5,000 crore insulin market including Actrapid, Insulatard, Insulin Detemir, Levemir and Xultophy, which are marketed primarily in the format of pre-filled disposable pen and cartridges (Penfill and ...
In 2004, Levemir – a long-acting modern insulin – was launched ... Liraglutide, a GLP-1 product for treatment of type 2 diabetes, enters phase 3 trials. Novo Nordisk launches its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results